2017 Q3 Form 10-Q Financial Statement
#000156459017022829 Filed on November 08, 2017
Income Statement
Concept | 2017 Q3 | 2016 Q3 |
---|---|---|
Revenue | $0.00 | $0.00 |
YoY Change | ||
Cost Of Revenue | ||
YoY Change | ||
Gross Profit | ||
YoY Change | ||
Gross Profit Margin | ||
Selling, General & Admin | $1.230M | $1.160M |
YoY Change | 6.03% | -34.83% |
% of Gross Profit | ||
Research & Development | $3.465M | $2.100M |
YoY Change | 65.0% | -16.25% |
% of Gross Profit | ||
Depreciation & Amortization | ||
YoY Change | ||
% of Gross Profit | ||
Operating Expenses | $4.692M | $3.264M |
YoY Change | 43.74% | -23.88% |
Operating Profit | -$4.692M | -$3.264M |
YoY Change | 43.72% | -23.88% |
Interest Expense | -$270.0K | -$480.0K |
YoY Change | -43.75% | 4554.77% |
% of Operating Profit | ||
Other Income/Expense, Net | -$1.140M | -$60.00K |
YoY Change | 1800.0% | -86.62% |
Pretax Income | -$6.100M | -$3.810M |
YoY Change | 60.1% | -19.62% |
Income Tax | ||
% Of Pretax Income | ||
Net Earnings | -$6.100M | -$3.810M |
YoY Change | 60.1% | -19.56% |
Net Earnings / Revenue | ||
Basic Earnings Per Share | ||
Diluted Earnings Per Share | -$222.1K | -$200.6K |
COMMON SHARES | ||
Basic Shares Outstanding | 27.47M | |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2017 Q3 | 2016 Q3 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | $9.800M | $14.60M |
YoY Change | -32.88% | -16.57% |
Cash & Equivalents | $2.568M | |
Short-Term Investments | $7.300M | $11.60M |
Other Short-Term Assets | $1.700M | $1.000M |
YoY Change | 70.0% | -28.57% |
Inventory | ||
Prepaid Expenses | ||
Receivables | ||
Other Receivables | ||
Total Short-Term Assets | $11.50M | $15.60M |
YoY Change | -26.28% | -17.6% |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | ||
YoY Change | ||
Goodwill | ||
YoY Change | ||
Intangibles | ||
YoY Change | ||
Long-Term Investments | ||
YoY Change | ||
Other Assets | $300.0K | $700.0K |
YoY Change | -57.14% | 775.0% |
Total Long-Term Assets | $339.4K | $700.0K |
YoY Change | -51.51% | 775.0% |
TOTAL ASSETS | ||
Total Short-Term Assets | $11.50M | $15.60M |
Total Long-Term Assets | $339.4K | $700.0K |
Total Assets | $11.84M | $16.30M |
YoY Change | -27.37% | -14.27% |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $1.555M | $900.0K |
YoY Change | 72.83% | 124.06% |
Accrued Expenses | $2.800M | $1.000M |
YoY Change | 180.0% | -23.08% |
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | $0.00 | $2.800M |
YoY Change | -100.0% | |
Long-Term Debt Due | $3.200M | |
YoY Change | ||
Total Short-Term Liabilities | $9.600M | $6.100M |
YoY Change | 57.38% | 6.6% |
LONG-TERM LIABILITIES | ||
Long-Term Debt | $0.00 | $0.00 |
YoY Change | ||
Other Long-Term Liabilities | $0.00 | |
YoY Change | ||
Total Long-Term Liabilities | $0.00 | $0.00 |
YoY Change | -100.0% | |
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $9.600M | $6.100M |
Total Long-Term Liabilities | $0.00 | $0.00 |
Total Liabilities | $9.600M | $6.100M |
YoY Change | 57.38% | 6.24% |
SHAREHOLDERS EQUITY | ||
Retained Earnings | ||
YoY Change | ||
Common Stock | ||
YoY Change | ||
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | $2.200M | $10.20M |
YoY Change | ||
Total Liabilities & Shareholders Equity | $11.80M | $16.30M |
YoY Change | -27.61% | -14.27% |
Cashflow Statement
Concept | 2017 Q3 | 2016 Q3 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | -$6.100M | -$3.810M |
YoY Change | 60.1% | -19.56% |
Depreciation, Depletion And Amortization | ||
YoY Change | ||
Cash From Operating Activities | -$3.330M | -$2.660M |
YoY Change | 25.19% | -21.76% |
INVESTING ACTIVITIES | ||
Capital Expenditures | ||
YoY Change | ||
Acquisitions | ||
YoY Change | ||
Other Investing Activities | $1.400M | $440.0K |
YoY Change | 218.18% | -113.5% |
Cash From Investing Activities | $1.400M | $440.0K |
YoY Change | 218.18% | -113.5% |
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | 1.110M | 110.0K |
YoY Change | 909.09% | -115.49% |
NET CHANGE | ||
Cash From Operating Activities | -3.330M | -2.660M |
Cash From Investing Activities | 1.400M | 440.0K |
Cash From Financing Activities | 1.110M | 110.0K |
Net Change In Cash | -820.0K | -2.110M |
YoY Change | -61.14% | -71.37% |
FREE CASH FLOW | ||
Cash From Operating Activities | -$3.330M | -$2.660M |
Capital Expenditures | ||
Free Cash Flow | ||
YoY Change |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2017Q3 | vktx |
Convertible Notes Payable Discount Current
ConvertibleNotesPayableDiscountCurrent
|
662588 | |
CY2016Q4 | vktx |
Convertible Notes Payable Discount Current
ConvertibleNotesPayableDiscountCurrent
|
675589 | |
CY2017Q3 | vktx |
Prepaid Clinical Trial Costs
PrepaidClinicalTrialCosts
|
1346171 | |
CY2016Q4 | vktx |
Prepaid Clinical Trial Costs
PrepaidClinicalTrialCosts
|
541603 | |
CY2017Q3 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
39341 | |
CY2017Q3 | us-gaap |
Assets
Assets
|
11839444 | |
CY2017Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1555472 | |
CY2017Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
2837392 | |
CY2016Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
1237122 | |
CY2016Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
3264282 | |
CY2017Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4691531 | |
CY2016Q3 | vktx |
Change In Fair Value Of Debt Conversion Features
ChangeInFairValueOfDebtConversionFeatures
|
-64514 | |
CY2017Q3 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
256596 | |
CY2017Q3 | vktx |
Amortization Of Financing Costs Equity Transactions
AmortizationOfFinancingCostsEquityTransactions
|
17568 | |
CY2016Q3 | vktx |
Amortization Of Financing Costs Equity Transactions
AmortizationOfFinancingCostsEquityTransactions
|
45852 | |
CY2016Q3 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
431227 | |
CY2017Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3464639 | |
CY2016Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3264282 | |
CY2017Q3 | vktx |
Change In Fair Value Of Debt Conversion Features
ChangeInFairValueOfDebtConversionFeatures
|
-1136074 | |
us-gaap |
Interest Paid
InterestPaid
|
122739 | ||
us-gaap |
Stock Issued1
StockIssued1
|
1800000 | ||
vktx |
Unpaid Deferred Initial Public Offering And Other Financing Costs
UnpaidDeferredInitialPublicOfferingAndOtherFinancingCosts
|
219509 | ||
vktx |
Repayments Of Notes Payable In Stock
RepaymentsOfNotesPayableInStock
|
1200000 | ||
CY2017Q3 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
7274037 | |
CY2017Q3 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
|
3318 | |
CY2017Q3 | vktx |
Available For Sale Securities In Unrealized Gain Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableForSaleSecuritiesInUnrealizedGainPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
|
0 | |
CY2016Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
12594380 | |
dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2012-09-24 | ||
dei |
Entity Incorporation State Country Name
EntityIncorporationStateCountryName
|
Delaware | ||
us-gaap |
Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
|
Three months or less | ||
CY2016Q3 | us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
19482162 | |
us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
24939198 | ||
CY2017Q3 | us-gaap |
Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
|
16 | |
CY2016Q4 | us-gaap |
Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
|
25 | |
us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain reclassifications have been made to certain of the prior years’ financial statements to conform to the current year presentation.</p></div> | ||
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements relate to determining the fair value of the debt conversion feature liability and accounting for certain commitments. Actual results could differ from those estimates.</p></div> | ||
us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and marketable securities. The Company maintains deposits in federally insured depository institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company has established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p></div> | ||
CY2016Q2 | vktx |
Additional Warrants Granted To Underwriters
AdditionalWarrantsGrantedToUnderwriters
|
1125000 | |
CY2016Q2 | vktx |
Additional Warrants Sold As Result Of Over Allotment Exercise
AdditionalWarrantsSoldAsResultOfOverAllotmentExercise
|
1125000 | |
CY2016Q2 | us-gaap |
Share Price
SharePrice
|
0.01 | |
us-gaap |
Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
|
15590113 | ||
CY2017Q3 | us-gaap |
Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
|
245096 | |
CY2016Q3 | us-gaap |
Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
|
490191 | |
us-gaap |
Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
|
273257 | ||
us-gaap |
Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
|
537974 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
17312283 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
14240487 | ||
us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | ||
CY2017Q3 | us-gaap |
Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
|
0 | |
us-gaap |
Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
|
0 | ||
CY2016 | us-gaap |
Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
|
0 | |
CY2016 | vktx |
Debt Instrument Current Maturities Due Date
DebtInstrumentCurrentMaturitiesDueDate
|
2016 | |
CY2016Q1 | vktx |
Debt Instrument Current Maturities Due Date
DebtInstrumentCurrentMaturitiesDueDate
|
2017 | |
CY2017Q2 | vktx |
Debt Instrument Current Maturity Date
DebtInstrumentCurrentMaturityDate
|
2018-05-21 | |
vktx |
Date Of Registration Rights Agreement Amendment
DateOfRegistrationRightsAgreementAmendment
|
2016-01-22 | ||
CY2016Q2 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
7754286 | |
CY2016Q2 | vktx |
Underwriting Discounts Commissions And Other Offering Expenses
UnderwritingDiscountsCommissionsAndOtherOfferingExpenses
|
1631964 | |
CY2016Q2 | us-gaap |
Shares Issued Price Per Share
SharesIssuedPricePerShare
|
1.25 | |
CY2016Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
1.50 | |
CY2016Q2 | vktx |
Additional Shares Offered Under Underwriting Agreement
AdditionalSharesOfferedUnderUnderwritingAgreement
|
1125000 | |
CY2016Q2 | vktx |
Underwriters Grant Period Option
UnderwritersGrantPeriodOption
|
P45D | |
CY2014Q1 | us-gaap |
Deferred Compensation Arrangement With Individual Common Stock Reserved For Future Issuance
DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
|
1000000 | |
CY2014Q1 | us-gaap |
Deferred Compensation Arrangement With Individual Exercise Price
DeferredCompensationArrangementWithIndividualExercisePrice
|
0.01 | |
CY2014Q1 | vktx |
Number Of Tranches
NumberOfTranches
|
2 | |
CY2014Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
168000 | |
CY2015Q2 | us-gaap |
Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
|
633810 | |
CY2015Q2 | vktx |
Shares Repurchase Price Per Share
SharesRepurchasePricePerShare
|
0.00001 | |
CY2015Q2 | us-gaap |
Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
|
366190 | |
CY2015Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
61556 | |
CY2016Q2 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
7500000 | |
CY2016Q2 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
7500000 | |
CY2016Q4 | us-gaap |
Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
|
731048 | |
CY2017Q3 | vktx |
Convertible Notes Payoff Value Current
ConvertibleNotesPayoffValueCurrent
|
1926491 | |
CY2016Q4 | vktx |
Convertible Notes Payoff Value Current
ConvertibleNotesPayoffValueCurrent
|
1990032 | |
CY2016 | us-gaap |
Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
|
0.05 | |
CY2016Q1 | us-gaap |
Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
|
0.025 | |
CY2016Q2 | vktx |
Class Of Warrants Or Rights Expiry Date
ClassOfWarrantsOrRightsExpiryDate
|
2021-04-13 | |
CY2016Q2 | vktx |
Over Allotment Option Exercised
OverAllotmentOptionExercised
|
1125000 | |
CY2016Q2 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
1125000 | |
CY2016Q2 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
1283400 | |
CY2016Q2 | vktx |
Underwriting Discounts Commissions And Other Offering Expenses
UnderwritingDiscountsCommissionsAndOtherOfferingExpenses
|
111600 | |
CY2017Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
344128 | |
CY2016Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
320953 | |
CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
883837 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
884534 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
178477 | ||
CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1589894 | |
CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
582194 | |
CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.28 | |
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.24 | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P8Y4M20D | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.89 | ||
CY2017Q3 | vktx |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableIntrinsicValue
|
118881 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.8510 | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y10M28D | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0196 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | ||
us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
0 | ||
CY2017Q3 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
10.00 | |
vktx |
Description Of Warrant
DescriptionOfWarrant
|
The warrant is exercisable for cash or on a cashless basis at a per share exercise price equal to $10.00 commencing on April 28, 2016, one year following the date of the prospectus filed with the SEC relating to the IPO, and expiring on April 28, 2020. The warrant also provides for registration rights upon request, under certain circumstances. The piggyback registration right provided in connection with the warrant will terminate on April 28, 2022. | ||
vktx |
Warrant Expiration Date
WarrantExpirationDate
|
2022-04-28 | ||
vktx |
Initial Public Offering Expiration Date
InitialPublicOfferingExpirationDate
|
2020-04-28 | ||
vktx |
Class Of Warrants Or Rights Expiry Date
ClassOfWarrantsOrRightsExpiryDate
|
2021-04-13 | ||
CY2017Q3 | us-gaap |
Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
|
62818 | |
CY2017Q3 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
190337 | |
CY2017Q3 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
253155 |